Enrasentan

SB 217242

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Pandey S, Stewart D, Dawood F, et al. The endothelin blocker SB-217242 preserves myocardial function in a chronic myocarditis model of heart failure. Circulation 1995 Oct; 92 (I Suppl.): 61
Google Scholar
Willette RN, Minehart H, Ellison J, et al. Effects of endothelin receptor antagonism and angiotensin-converting enzyme inhibition on cardiac and renal remodelling in the rat. J Cardiovasc Pharmacol 1998; 31 (1 Suppl.): 277–83
Article Google Scholar
Chandra S, Clark LV, Coatney RW, et al. Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointimaformation. Circulation 1998 Jun 9; 97: 2252–8
Article PubMed CAS Google Scholar
Barone FC, White RF, Elliott JD, et al. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J Cardiovasc Pharmacol 1995; 26 (3 Suppl.): 404–7
Google Scholar
Elwood W. Expanding horizons for endothelin-receptor antagonists. Inpharma 1998 Jun 27; 1143: 9–10
Google Scholar

Enrasentan. Drugs R&D 2, 24–25 (1999). https://doi.org/10.2165/00126839-199902010-00005

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.